Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
scientific article published on 9 July 2009
Author/s
author: Elisabetta Abruzzese, Serena Merante, Francesca Palandri, Simona Soverini, Cristina Papayannidis, Gianantonio Rosti, Fausto Castagnetti, Giovanni Martinelli, Gabriele Gugliotta, Michele Baccarani, Ilaria Iacobucci, Daniela Cilloni, Stefania Paolini, Angela Poerio, Alessandra Gnani, Sabrina Colarossi, Marilina Amabile, Antonella Gozzini, Ester Orlandi
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.